Effect of combination of taurine and azelaic acid on antimelanogenesis in murine melanoma cells.
BACKGROUND
Pigmentation in human skin is an important defense mechanism against sunlight or oxidative stress. Despite the protective role of melanin, abnormal hyperpigmentation such as freckles and chloasma sometimes can be serious aesthetic problems. Because of these effects of hyperpigmentation, people have considered the effect of depigmentation. Azelaic acid (AZ) is a saturated dicarboxylic acid found naturally in wheat, rye, and barley. Previously, we showed that AZ inhibited melanogenesis. In this study, we investigated the antimelanogenic activity of combination of AZ and taurine (Tau) in B16F10 mouse melanoma cells.


METHODS
The mouse melanoma cell line B16F10 was used in the study. We measured melanin contents and tyrosinase activity. To gain the change of protein expression, we carried out western blotting.


RESULTS
We investigated that AZ combined with taurine (Tau) show more inhibitory effects in melanocytes than the treatment of AZ alone. AZ combined with Tau inhibited the melanin production and tyrosinase activity of B16F10 melanoma cells without significant cytotoxicity. Also inhibitory effects after treatment with these combined chemical are stronger than AZ alone on melanogenesis.


CONCLUSIONS
These findings indicate that AZ with Tau might play an important role in the regulation of melanin formation and be useful as effective ingredients in antimelanogesis.
Yu
Ji Sun
JS
Biochemistry Laboratory, College of Pharmacy, Sookmyung Women's University, 52 Hyochangwon-gil, Yongsan-gu Seoul, 140-742, Korea. imjisun@hotmail.com
Kim
An Keun
AK
D000818:Animals; D045744:Cell Line, Tumor; D003998:Dicarboxylic Acids / Q000378:metabolism / Q000494:pharmacology* / Q000627:therapeutic use; D004338:Drug Combinations; D006801:Humans; D008543:Melanins / Q000096:biosynthesis*; D008544:Melanocytes / Q000166:cytology / Q000187:drug effects* / Q000378:metabolism; D008545:Melanoma / Q000188:drug therapy* / Q000473:pathology; D051379:Mice; D051739:Microphthalmia-Associated Transcription Factor / Q000378:metabolism; D014442:Monophenol Monooxygenase / Q000378:metabolism; D010858:Pigmentation; D012878:Skin Neoplasms / Q000188:drug therapy* / Q000473:pathology; D013654:Taurine / Q000378:metabolism / Q000494:pharmacology* / Q000627:therapeutic use
D003998:Dicarboxylic Acids; D004338:Drug Combinations; D008543:Melanins; D051739:Microphthalmia-Associated Transcription Factor; D013654:Taurine; D014442:Monophenol Monooxygenase; C010038:azelaic acid
Arch Dermatol Res. 1990;282(3):168-71
2114832
J Biol Chem. 1997 Jan 3;272(1):503-9
8995290
J Cosmet Dermatol. 2007 Sep;6(3):195-202
17760699
Pigment Cell Res. 2000 Apr;13(2):60-9
10841026
Cell. 1993 Jul 30;74(2):395-404
8343963
Cancer Res. 1986 Feb;46(2):493-7
3079662
Pigment Cell Res. 2000 Aug;13(4):230-40
10952390
J Cell Sci. 2003 May 1;116(Pt 9):1699-706
12665551
Pigment Cell Res. 2003 Apr;16(2):101-10
12622786
FEBS Lett. 1996 Mar 4;381(3):165-8
8601447
Semin Cutan Med Surg. 2009 Jun;28(2):77-85
19608057
Biosci Biotechnol Biochem. 2006 Feb;70(2):532-4
16495675
Nature. 1998 Jan 15;391(6664):298-301
9440696
Pigment Cell Res. 1997 Feb-Apr;10(1-2):12-24
9170158
Skin Therapy Lett. 2004 Jun-Jul;9(6):1-3
15334278
Arch Dermatol Res. 2008 Jul;300(6):325-9
18478240
Chem Pharm Bull (Tokyo). 2002 Mar;50(3):309-11
11911191
Int J Dermatol. 1995 Feb;34(2):75-84
7737781
Indian J Dermatol. 2009;54(4):303-9
20101327